Novel HER2 Conjugate Promising as Salvage for Solid Tumors
A small trial of a new antibody-drug conjugate that targets HER2 produced an objective response rate of 43% in patients... Read More
Save the Date!
Our 10th Anniversary Celebration on November 16th
is a celebration not to be missed!
Saturday, November 16
Peninsula Golf & Country Club
701 Madera Drive San Mateo, California
Support Research for a Cure
Every contribution to Gastric Cancer Foundation makes a difference. Honor a loved one, make a tribute to someone’s memory, honor a happy occasion by making a meaningful donation.
-
Foundation Board Members Meet with Gastric Cancer Registry
Foundation board members recently visited the Gastric Cancer Registry at Stanford University’s Genome Technology Center to receive updates and discuss... Read More-
Merck Provides Update on Phase 3 KEYNOTE-062 Trial Evaluating KEYTRUDA
Merck finds Keytruda no better than chemo as a first-line treatment for gastric cancer, according to a Phase 3 study.... Read More -
How inflammation causes gastric cancer
In a study, scientists blocked a protein pathway that causes the proliferation of gastric epithelial cells from H. Pylori infection... Read More 
Intestinal and diffuse gastric cancer: a retrospective study comparing primary sites
A retrospective study compares the significant difference in the spread patterns of intestinal gastric cancer to that of diffuse subtype... Read More
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial
In the randomized, phase II (part 1) ATTRACTION-4 trial, nivolumab combined with chemotherapy [S-1 plus oxaliplatin (SOX) or capecitabine plus... Read More
Comparison of Four Front-Line Doublets in Asian Patients With Metastatic Gastric Cancer
In a Phase II trial, four front-line chemotherapy doublets were compared for treatment of patients with metastatic gastric cancer. While... Read More
Second primary cancers and survival in patients with gastric cancer: association with prediagnosis lifestyles
Heavy alcohol consumption and an unhealthy diet prior to a diagnosis of gastric cancer can affect treatment outcomes, a new... Read More
Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer
A new study suggests that adding docetaxel to fluoropyrimidine post surgery is effective in stage 3 gastric cancer.
Nutrition for Patients With Mucositis
Dr. Jann Arends discusses the importance of considering nutritional treatment for #cancer patients with mucositis, painful inflammation and ulceration of... Read More
Perioperative Fluorouracil + Leucovorin, Oxaliplatin, and Docetaxel vs Fluorouracil or Capecitabine + Cisplatin and Epirubicin for Locally Advanced, Resectable Gastric or GE Junction Adenocarcinoma
A phase II/III trial investigated a chemotherapy triplet, FLOT (docetaxel, oxaliplatin, 5-FU/LV), as perioperative therapy in resectable gastroesophageal cancers compared... Read More
Effect of Vitamin D Supplementation on Relapse-Free Survival Among Patients With Digestive Tract Cancers
A large randomized trial concluded that Vitamin D supplementation does not improve relapse-free survival in patients with cancers of the... Read More
Cancer prevention drug also disables H. pylori bacterium
Researchers have discovered that a medicine currently being tested as a chemoprevention agent for multiple types of cancer also disables... Read More
Updated Clinical Data from Combination of Margetuximab and Pembrolizumab in Gastric Cancer Presented at 2019 ASCO Gastrointestinal Cancers Symposium
“We continue to be very encouraged by the tolerability and antitumor activity of margetuximab with an anti-PD-1 mAb, an investigational,... Read More
Taiho Oncology and Servier Present Data on LONSURF (trifluridine/tipiracil) at ASCO 2019 Gastrointestinal Cancers Symposium (ASCO GI)
A new study evaluating LONSURF in patients with previously treated metastatic gastric cancer is consistent with the overall study results... Read More
Five Prime Therapeutics Presents Data from Safety Lead-in to Phase 3 FIGHT Trial of Bemarituzumab at 2019 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium
“Gastric cancer with FGFR2b overexpression or FGFR2 gene amplification is associated with a poor prognosis for patients with advanced disease,”... Read More
Safety and efficacy of durvalumab following trimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Early efficacy results from Big Ten Cancer Research Consortium study
Presented at last week’s ASCO Gastrointestinal Cancers Symposium, noteworthy studies incuded new approaches to treating and managing gastric cancer including... Read More
A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer
Researchers evaluated the addition of the AKT inhibitor ipatasertib to mFOLFOX6 for patients with gastric cancer.
Citrus fruit intake and gastric cancer: The stomach cancerpooling (StoP) project consortium
A new study in International Journal of Cancer evaluated the link between eating citrus fruit and gastric cancer risk, finding... Read More
Biotech Imugene ‘encouraged’ by data for HER2 vaccine in gastric cancer
An early stage drug tested in a new study shows promising results for gastric cancer patients.
Monthly Newsletter
We’ll deliver our monthly newsletter to your Inbox with Foundation updates, news about cutting edge research and trends in the field, and how to make a difference.